- November 8, 2023
- | Vittoria
Navigating the challenges of cell therapies
Vittoria’s innovative Senza5 platform, with its unique CD5-targeting approach, aims to enhance the efficacy, safety, and speed of cell therapies.
- November 6, 2023
- | CoRegen
The Legend Steve Gorlin’s Golden Rules
This week, the Business of Biotech sits down with the legendary biotech investor Steve Gorlin, now CEO of CoRegen, for a conversation on his golden rules for picking winners.
- November 3, 2023
- | eFFECTOR
Locks on Translation Initiation May Restrain Cancer
Effector Therapeutics is working on selective translation regulator inhibitors (STRIs).
- October 30, 2023
- | GigaGen
Can gene editing drive out HIV and hepatitis viruses from inside cells?
GigaGen, a subsidiary of Barcelona-based Grifols, aims to file an investigational new drug application next year, ahead of an initial trial of its recombinant polyclonal antibody therapy for chronic HBV infection
- October 30, 2023
- | GigaGen
Can gene editing drive out HIV and hepatitis viruses from inside cells?
GigaGen, a subsidiary of Barcelona-based Grifols, aims to file an investigational new drug application next year, ahead of an initial trial of its recombinant polyclonal antibody therapy for chronic HBV infection.
- October 24, 2023
- | GRIFOLS
CTAD 2023: Grifols/Araclon Ponder Next Steps For ABvac40 After Phase II Readout
The Phase II trial was not powered to show statistical significance on cognitive efficacy, but early Alzheimer’s patients treated with Araclon/Grifols’ anti-Aβ40 vaccine had slower decline by some measures.
- October 13, 2023
- | MindMed
Orlando researchers are giving depressed, anxious people psychedelics
The study is run by Mind Medicine, a biotech pharmaceutical company seeking approval for its proprietary form of LSD.
- October 13, 2023
- | Reviva Pharmaceuticals
Schizophrenia drug developer eyes late-stage clinical trial data this month
Reviva was founded in 2006 and has survived the double whammy of the Great
Recession and the Covid-19 pandemic.
